文献速递膀胱癌与上尿路尿路上皮癌

浆细胞样变异型膀胱尿路上皮癌:临床病理特征与生存结局的系统综述与Meta分析

Plasmacytoid Variant Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-Analysis of Clinicopathological Features and Survival Outcomes.
PubMed 文献 · J Urol · 2020-01-31

该系统综述与Meta分析纳入8项研究,比较浆细胞样变异型膀胱尿路上皮癌与传统尿路上皮癌的临床病理特征和生存结局。浆细胞样变异型与更高的pT3及以上分期、淋巴结转移及切缘阳性风险相关,校正后总死亡率接近显著升高,为独立预后因素。

要点

  • 浆细胞样变异型膀胱尿路上皮癌pT3及以上风险显著高于传统型(OR 3.84)。
  • 淋巴结转移、输尿管切缘阳性及膀胱周围软组织切缘阳性风险均显著增高。
  • 校正后总死亡率接近显著升高(HR 1.62,p=0.06),为独立预后因素。

核心结论

  • 浆细胞样变异型膀胱尿路上皮癌与传统型相比,与不良临床病理特征和更差的总死亡率强烈相关,是总生存的独立预后因素。

研究设计与样本

  • 遵循PRISMA指南的系统综述与Meta分析,检索PubMed/MEDLINE、Embase和Cochrane Library至2019年6月,纳入8项研究。

主要发现

  • 浆细胞样变异型患者根治性膀胱切除术后pT3及以上频率更高(OR 3.84,95%CI 1.63-9.03,p=0.002)。
  • 淋巴结转移风险更高(OR 2.58,95%CI 1.15-5.76,p=0.02)。
  • 输尿管切缘阳性风险更高(OR 12.18,95%CI 4.62-32.13,p<0.00001)。
  • 膀胱周围软组织切缘阳性风险更高(OR 12.31,95%CI 5.15-29.41,p<0.00001)。
  • 癌症特异性死亡率无差异(HR 1.40,95%CI 0.82-2.40,p=0.22),但校正后总死亡率接近显著升高(HR 1.62,95%CI 0.98-2.68,p=0.06)。

临床怎么用

  • 临床遇到浆细胞样变异型膀胱尿路上皮癌应警惕高分期、淋巴结转移和切缘阳性风险,需更积极的术前评估和手术规划。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The clinicopathological features and treatment outcomes of plasmacytoid variant-urothelial carcinoma of the bladder have not been fully understood. We evaluated the clinicopathological characteristics and survival outcomes of plasmacytoid variant-urothelial carcinoma of the bladder compared to conventional urothelial carcinoma of the bladder. MATERIALS AND METHODS: A systematic review was performed following the PRISMA guideline. PubMed®/MEDLINE®, Embase® and Cochrane Library were searched up to June 2019. The differences in the clinicopathological features (stage pT3 or greater, lymph node metastasis, ureteral margin positive and perivesical soft tissue margin positive status) and survival outcomes (overall mortality and cancer specific mortality) between plasmacytoid variant-urothelial carcinoma of the bladder and conventional urothelial carcinoma of the bladder were compared. The GRADE approach was used for rating the certainty of evidence. RESULTS: Eight studies were included. Patients with plasmacytoid variant-urothelial carcinoma of the bladder had a higher frequency of stage pT3 or greater (OR 3.84, 95% CI 1.63-9.03, p=0.002) and risk of lymph node metastasis (OR 2.58, 95% CI 1.15-5.76, p=0.02), ureteral margin positive (OR 12.18, 95% CI 4.62-32.13, p <0.00001) and perivesical soft tissue margin positive (OR 12.31, 95% CI 5.15-29.41, p <0.00001) status after radical cystectomy than those with conventional urothelial carcinoma of the bladder. Although there was no difference in cancer specific mortality (HR 1.40, 95% CI 0.82-2.40, p=0.22) between plasmacytoid variant-urothelial carcinoma of the bladder and conventional urothelial carcinoma of the bladder, plasmacytoid variant-urothelial carcinoma of the bladder had worse survival outcomes (overall mortality) than conventional urothelial carcinoma of the bladder approaching the borderline of significance (HR 1.62, 95% CI 0.98-2.68, p=0.06) when adjusted for other clinicopathological characteristics. CONCLUSIONS: Plasmacytoid variant-urothelial carcinoma of the bladder was strongly associated with adverse clinicopathological features and worse overall mortality compared to conventional urothelial carcinoma of the bladder after adjusting for other clinicopathological parameters, and plasmacytoid variant histology of urothelial carcinoma of the bladder is an independent prognostic factor for overall survival.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Kim DK, Kim JW, Ro JY, et al. Plasmacytoid Variant Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-Analysis of Clinicopathological Features and Survival Outcomes. J Urol. 2020. PMID: 32003614. doi:10.1097/JU.0000000000000794

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。